TF and cancer: Notably, the similar stratification of patients and controls by SNA binding and anti-TF IgA level as has been done for SNA and IgM, showed that patients with high SNA binding and low IgA level demonstrated the ACC value equal to 52%, which allowed no cancer-noncancer group discrimination, thus supporting the idea that IgM is the main target for changes in the increased anti-TF antibody sialylation in cancer.